Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 19Lymphoma 17Lymphoma, Large B-Cell, Diffuse 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 14Hodgkin Disease 13Multiple Myeloma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 9Glioblastoma 9Lymphoma, B-Cell, Marginal Zone 8Burkitt Lymphoma 8Brain Neoplasms 8Sezary Syndrome 7Neoplasms 7Lymphoma, T-Cell, Cutaneous 7Leukemia 7Congenital Abnormalities 7Unspecified Adult Solid Tumor, Protocol Specific 6Recurrence 6Neuroblastoma 6Mycosis Fungoides 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large-Cell, Anaplastic 6Breast Neoplasms, Male 6Sarcoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5

Interventions

Cisplatin 15Gemcitabine 7Fluorouracil 6Docetaxel 6Radiotherapy, Intensity-Modulated 5Oxaliplatin 4Capecitabine 4pembrolizumab 3Radiotherapy 3Carboplatin 3Acupuncture Therapy 3Psychiatric Rehabilitation 2Paclitaxel 2Nicotine 2Counseling 2Cetuximab 2Celecoxib 2Bupropion 2tislelizumab 1spartalizumab 1sargramostim 1motexafin gadolinium 1fosaprepitant 1fialuridine 1endostar protein 1cc-486 1apatinib 1Zoledronic Acid 1Zinc Oxide 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Nasopharyngeal Neoplasms × Vorinostat × Clear all
NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

University of Washington

Phase 1/2 Completed
50 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡